We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.35%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.65B
AUM Growth
+$205M
Cap. Flow
-$69.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
39.13%
Holding
181
New
13
Increased
25
Reduced
35
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$17.1M
2
PFE icon
Pfizer
PFE
+$15.6M
3
BIIB icon
Biogen
BIIB
+$14.1M
4
MCK icon
McKesson
MCK
+$12.2M
5
AVTR icon
Avantor
AVTR
+$9.51M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
2
JNJ icon
Johnson & Johnson
JNJ
+$24.9M
3
HUM icon
Humana
HUM
+$18.5M
4
AZN icon
AstraZeneca
AZN
+$15.7M
5
MOH icon
Molina Healthcare
MOH
+$15.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.55%
2 Real Estate 1.68%
3 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FULC icon
151
Fulcrum Therapeutics
FULC
$283M
$426K 0.02%
+58,537
New +$382K
CYH icon
152
Community Health Systems
CYH
$412M
$382K 0.01%
88,335
– –
ACET icon
153
Adicet Bio
ACET
$86.4M
$361K 0.01%
2,521
– –
TCRX icon
154
TScan Therapeutics
TCRX
$47.3M
$326K 0.01%
200,000
– –
CDXS icon
155
Codexis
CDXS
$156M
$322K 0.01%
69,125
– –
MOR
156
DELISTED
MorphoSys AG American Depositary Shares
MOR
$293K 0.01%
81,867
– –
MNK
157
DELISTED
Mallinckrodt plc
MNK
$272K 0.01%
+35,048
New +$392K
DTIL icon
158
Precision BioSciences
DTIL
$182M
$267K 0.01%
7,484
– –
PCVX icon
159
Vaxcyte
PCVX
$7.73B
$240K 0.01%
+5,000
New +$196K
BDTX icon
160
Black Diamond Therapeutics
BDTX
$99.7M
$238K 0.01%
131,990
– –
DHC
161
Diversified Healthcare Trust
DHC
$2.13B
$231K 0.01%
357,720
– –
HARP
162
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$189K 0.01%
25,991
– –
PRAX icon
163
Praxis Precision Medicines
PRAX
$8.52B
$179K 0.01%
5,000
– –
NKTX icon
164
Nkarta
NKTX
$154M
$174K 0.01%
28,988
– –
FUSN
165
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$137K 0.01%
43,394
-58,537
-57% -$146K
ORKA
166
Oruka Therapeutics
ORKA
$5.72B
$76.6K ﹤0.01%
2,705
– –
SPPI
167
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$42.3K ﹤0.01%
114,670
– –
YARW
168
Yarrow Bioscience, Inc. Common Stock
YARW
$22.4M
$20.3K ﹤0.01%
150
– –
CRBP icon
169
Corbus Pharmaceuticals
CRBP
$165M
$17.1K ﹤0.01%
5,144
– –
ALR
170
DELISTED
AlerisLife Inc
ALR
$13.3K ﹤0.01%
24,237
– –
NXGL icon
171
NexGel
NXGL
$3.9M
$5.3K ﹤0.01%
4,243
– –
BLCM
172
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$4.32K ﹤0.01%
6,000
– –
DSGN icon
173
Design Therapeutics
DSGN
$797M
– –
-280,523
Closed -$4.69M
ACH
174
Accendra Health
ACH
$261M
– –
-225,117
Closed -$5.42M
RNAM
175
DELISTED
Avidity Biosciences
RNAM
– –
-64,618
Closed -$1.05M
4 5 6
7
8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Tekla Capital Management held 181 positions worth $2.65B, up 8.4% from $2.44B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q4 2022 filing shows 13 new, 25 increased, 35 reduced and 9 closed positions. Its largest new stake was Avantor: 459,488 shares worth $9.69M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q4 2022 buy was Avantor: 459,488 shares worth $9.69M.
  • Tekla Capital Management added most to Eli Lilly in Q4 2022, an estimated $17.1M increase.
  • Tekla Capital Management's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $26.5M.
  • Tekla Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $10.6M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.65B portfolio in Q4 2022.
  • Tekla Capital Management opened 13 new positions and closed 9 in Q4 2022.
  • Tekla Capital Management's portfolio value rose 8.4% quarter-over-quarter to $2.65B.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.